{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.0","upperLimit":"36.4","value":"28"},{"groupId":"OG001","lowerLimit":"4.0","upperLimit":"7.6","value":"4.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"44"}],"units":"Participants"}],"description":"TTP is defined as the interval between the date of randomization and the earliest documented evidence of disease progression based on the independent radiologic review.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ripretinib (150 mg) once daily in 28-day cycles until disease progression by Independent Radiologic Review (IRR) in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior therapies (therapies must include treatment with imatinib, sunitinib, and regorafenib).","id":"OG000","title":"Ripretinib"},{"description":"Placebo once daily in 28-day cycles until disease progression by Independent Radiologic Review (IRR) in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior therapies (therapies must include treatment with imatinib, sunitinib, and regorafenib).","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"ITT Population","reportingStatus":"POSTED","timeFrame":"From date of randomization to the earliest date of disease progression [through database cutoff 31-May-2019 (up to approximately 15 months)].","title":"Time to Tumor Progression (TTP) Based on Independent Radiologic Review","type":"SECONDARY","unitOfMeasure":"Weeks"}